InsidersTradesSigma
Dr. Reddy's Laboratories Limited: directors' dealings · India · SEBI (PIT + SAST)
SEBI:dr-reddys-laboratories-limitedIN·SEBI (PIT + SAST)Mcap 951.9Bn€
Explore the full management transaction log of Dr. Reddy's Laboratories Limited, a publicly traded company based in India. Shares trade on IN IN, under the supervision of SEBI (PIT + SAST). Market capitalisation: €951.9bn. The latest transaction was disclosed on 9 December 2025 — Purchase. Among the most active insiders: Dr. Reddy's Employees ESOS Trust. The full history is accessible without an account.
405
Insider Decl.
0
Thresholds
€33m
240 ops.
Buy Volume
€28m
164 ops.
Sell Volume
Financial data
FY ended March 2025 · cache
1331.20 €
Income statement
Revenue325.54 Bn€
Gross profit190.43 Bn€58% margin
Net income56.54 Bn€17.4% margin
Balance sheet & cash
Market cap951.85 Bn€
Total debt46.77 Bn€
Free Cash Flow12.03 Bn€
Last declaration on 9 December 2025
Declarations405 total
Executives●Purchase0SEBI
€51,5924,275 shares@ €12.0683
Equity Shares
SEBI:822ca6b2345cf2621e60ff9466315e91affff923·
Ideal exit: 5 Sept 2026 (T+270)
Executives●Purchase0SEBI
€60,5894,775 shares@ €12.6888
ADR/GDR/FCCB
SEBI:12397999a46a73696eb8b2cb38851e7b5df97759·
Ideal exit: 12 Jun 2026 (T+270)
Executives●Purchase0SEBI
€129,22510,495 shares@ €12.313
ADR/GDR/FCCB
SEBI:71816ffee125b52204b6af171b43c9529dd5ef46·
Ideal exit: 26 May 2026 (T+270)
Executives●Sale0SEBI
€95,9737,450 shares@ €12.8822
ADR/GDR/FCCB
SEBI:86d33db5422baec141b37128c053b753ec5e9f42·
Executives●Sale0SEBI
€95,9367,450 shares@ €12.8773
ADR/GDR/FCCB
SEBI:9a07849b7fe719b923089f65397e5e5162acfe70·
Executives●Purchase0SEBI
€111,3208,440 shares@ €13.1896
Equity Shares
SEBI:ca7e09c9c591c0642ad41a1868cf98765813d196·
Ideal exit: 20 Mar 2026 (T+270)
Executives●Purchase0SEBI
€19,7181,495 shares@ €13.1896
Equity Shares
SEBI:c774b42f99bc9c9c69c9dcdc47e081bdb5446006·
Ideal exit: 20 Mar 2026 (T+270)
Executives●Purchase0SEBI
€17,1291,250 shares@ €13.703
Equity Shares
SEBI:cbffd07a0456fe2014a1947757b32d1f55eba36d·
Ideal exit: 11 Mar 2026 (T+270)
Executives●Purchase0SEBI
€28,0912,050 shares@ €13.703
Equity Shares
SEBI:e7334e232c6c933eee2cf3cd4dfa11e5da1224c6·
Ideal exit: 11 Mar 2026 (T+270)
Executives●Purchase0SEBI
€22,8841,670 shares@ €13.703
Equity Shares
SEBI:e9ac179127cc280090adf9a413cd47f5985d558b·
Ideal exit: 11 Mar 2026 (T+270)
Executives●Purchase0SEBI
€99,0981,412 shares@ €70.1826
ADR/GDR/FCCB
SEBI:14339ac2b99aa3e6de215c668612c78ee42b8ce8·
Ideal exit: 17 Jun 2025 (T+270)
Executives●Purchase0SEBI
€111,8711,594 shares@ €70.1826
ADR/GDR/FCCB
SEBI:c792667a8e4f2aa03d7372d7e23b406ecdcaee9e·
Ideal exit: 17 Jun 2025 (T+270)
Executives●Sale0SEBI
€121,6681,700 shares@ €71.5692
ADR/GDR/FCCB
SEBI:485a090766fc1d5ae19b33ab176e9078af181b69·
Executives●Purchase0SEBI
€52,315704 shares@ €74.3117
ADR/GDR/FCCB
SEBI:b3e7e26b4f07a30cedee660c5ff6d5bbcdb58dc0·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€10,775145 shares@ €74.3117
ADR/GDR/FCCB
SEBI:6fa92ed9233363a2096a34f71bebddd2f15c6897·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€15,977215 shares@ €74.3117
ADR/GDR/FCCB
SEBI:b2a590e11b6e5f7bb729fc2e02c09600b6647802·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€92,8991,250 shares@ €74.3195
ADR/GDR/FCCB
SEBI:67ec9ba677b0f9f575bd752fa42dd722f5bce9ea·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€35,224474 shares@ €74.3117
ADR/GDR/FCCB
SEBI:dd58cd6759927e0612b21c8b7723db23a8dc4704·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€43,431594 shares@ €73.1163
ADR/GDR/FCCB
SEBI:7ca38455e4ae5753d0bed2779c66d7c4221db444·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€60,490814 shares@ €74.3117
ADR/GDR/FCCB
SEBI:242380ba5867de3db5bc86037cc0fc97b993c2ec·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€11,147150 shares@ €74.3117
ADR/GDR/FCCB
SEBI:98fb5c592eeec2578963d0b26554f66fbdd3c543·
Ideal exit: 26 May 2025 (T+270)
Executives●Purchase0SEBI
€5m27,635 shares@ €175.9821
ADR/GDR/FCCB
SEBI:5bd736ed73b8ad889442291f8e6dce5e6285d684·
Ideal exit: 4 May 2025 (T+270)
Executives●Sale0SEBI
€5m65,500 shares@ €74.2015
ADR/GDR/FCCB
SEBI:684be7024ba26d6180e0e5b111479e0c0404c6ba·
Executives●Purchase0SEBI
€42,437625 shares@ €67.8994
ADR/GDR/FCCB
SEBI:d2cb053c5c71d12be79b2aa234dd5992cd94263a·
Ideal exit: 11 Mar 2025 (T+270)
Executives●Purchase0SEBI
€9,234136 shares@ €67.8994
ADR/GDR/FCCB
SEBI:3787d4622c4c0ecbf4d063c5159a3894d0a22871·
Ideal exit: 11 Mar 2025 (T+270)
25 of 405 declarations
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited is an Indian pharmaceutical company that develops, manufactures, and markets a wide range of generic medications, branded drugs, and biologics. It is listed on the Bombay Stock Exchange.